With Trump victorious, biotech industry’s focus turns to his plans for FDA, FTC

Donald Trump’s victory in the U.S. presidential election Tuesday means change is coming for federal health agencies and the industries they regulate. It’s just not quite clear yet how dramatic that change might be.

Trump has pledged to “make America healthy again” and, in embracing Robert F. Kennedy Jr., a well-known critic of vaccines and pharmaceutical companies, has signaled such a campaign could feature unorthodox or disruptive ideas.